• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测乳腺癌女性患者的病理分期≥N2疾病

Predicting pathologic ≥N2 disease in women with breast cancer.

作者信息

Wanis Kerollos Nashat, Dong Wenli, Shen Yu, Meric-Bernstam Funda, Adesoye Taiwo, Kuerer Henry M, Caudle Abigail S, Tamirisa Nina, DeSnyder Sarah M, Sun Susie X, Bedrosian Isabelle, Singh Puneet, Cox Solange E, Hunt Kelly K, Hwang Rosa F

机构信息

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

NPJ Breast Cancer. 2025 May 22;11(1):46. doi: 10.1038/s41523-025-00757-4.

DOI:10.1038/s41523-025-00757-4
PMID:40404657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12098822/
Abstract

The distinction between pN1 and ≥pN2 breast cancer impacts treatment decisions. Using data from a single institution on women with cN0 invasive breast cancer who were treated with upfront surgery, had 1-3 positive SLNs, and underwent completion ALND, we used gradient boosted trees (XGBoost) to develop a model for predicting ≥pN2 disease using clinicopathologic variables. Model performance was tested in a held-out subsample (20%) and validated using data from the National Cancer Database (NCDB). Of 3574 patients with cN0 breast cancer, 587 underwent upfront surgery and had 1-3 positive SLNs. Of these, 415 (70.7%) underwent completion ALND, with 64 (15.4%) having ≥pN2 disease. The trained algorithm had an AUC of 0.87 (95% CI: 0.74, 0.97) in the held-out test data, and 0.78 (95% CI: 0.76, 0.79) in recent NCDB data where completion ALND was much less commonly performed. The number of positive SLNs and the total number of SLNs removed had the greatest influence on model predictions in the held-out test data. The developed model effectively estimates the probability of ≥pN2 disease in cN0 patients with positive SLNs, providing guidance for the management of patients with breast cancer.

摘要

pN1与≥pN2期乳腺癌之间的区别会影响治疗决策。利用来自单一机构的关于cN0期浸润性乳腺癌女性患者的数据,这些患者接受了 upfront 手术,前哨淋巴结(SLN)有1 - 3枚阳性,并接受了腋窝淋巴结清扫术(ALND),我们使用梯度提升树(XGBoost),根据临床病理变量建立了一个预测≥pN2期疾病的模型。在一个留出的子样本(20%)中测试了模型性能,并使用国家癌症数据库(NCDB)的数据进行验证。在3574例cN0期乳腺癌患者中,587例接受了 upfront 手术且前哨淋巴结有1 - 3枚阳性。其中,415例(70.7%)接受了腋窝淋巴结清扫术,64例(15.4%)为≥pN2期疾病。在留出的测试数据中,训练后的算法曲线下面积(AUC)为0.87(95%可信区间:0.74,0.97),在近期NCDB数据中为0.78(95%可信区间:0.76,0.79),在该数据集中腋窝淋巴结清扫术的实施频率要低得多。在前哨淋巴结阳性的数量和切除的前哨淋巴结总数中,在前瞻性测试数据中对模型预测的影响最大。所建立的模型有效地估计了前哨淋巴结阳性的cN0患者发生≥pN2期疾病的概率,为乳腺癌患者的管理提供了指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6d5/12098822/dc192929a41f/41523_2025_757_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6d5/12098822/7e689fe58f9b/41523_2025_757_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6d5/12098822/dc192929a41f/41523_2025_757_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6d5/12098822/7e689fe58f9b/41523_2025_757_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6d5/12098822/dc192929a41f/41523_2025_757_Fig2_HTML.jpg

相似文献

1
Predicting pathologic ≥N2 disease in women with breast cancer.预测乳腺癌女性患者的病理分期≥N2疾病
NPJ Breast Cancer. 2025 May 22;11(1):46. doi: 10.1038/s41523-025-00757-4.
2
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy.新辅助化疗后临床淋巴结阴性乳腺癌中残留淋巴结疾病的意义
Ann Surg Oncol. 2025 Feb;32(2):922-930. doi: 10.1245/s10434-024-16382-7. Epub 2024 Oct 23.
3
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?是否进行解剖:对于临床淋巴结阴性的绝经后乳腺癌患者,我们能否预测存在 4 个或更多腋窝淋巴结转移?
Ann Surg Oncol. 2023 Dec;30(13):8327-8334. doi: 10.1245/s10434-023-14245-1. Epub 2023 Sep 5.
4
Are Clinically Node-Negative Patients with a Positive Preoperative Axillary Lymph Node Biopsy Appropriate Candidates for Sentinel Lymph Node Biopsy?术前腋窝淋巴结活检呈阳性的临床淋巴结阴性患者是否适合前哨淋巴结活检?
Ann Surg Oncol. 2025 Jan;32(1):92-97. doi: 10.1245/s10434-024-16321-6. Epub 2024 Oct 12.
5
Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value?乳腺癌患者术前腋窝淋巴结分期的腋窝超声检查:它有附加价值吗?
Breast. 2013 Dec;22(6):1108-13. doi: 10.1016/j.breast.2013.09.002. Epub 2013 Oct 2.
6
Omission of Intraoperative Frozen Section May Reduce Axillary Overtreatment Among Clinically Node-Negative Patients Having Upfront Mastectomy.对于行 upfront 乳房切除术且临床淋巴结阴性的患者,术中冰冻切片的省略可能会减少腋窝过度治疗。
Ann Surg Oncol. 2022 Dec;29(13):8037-8043. doi: 10.1245/s10434-022-12238-0. Epub 2022 Aug 11.
7
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.新辅助化疗后前哨淋巴结阳性乳腺癌患者的前哨淋巴结手术:ACOSOG Z1071(Alliance)临床试验。
JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.
8
The intraoperative assessment of sentinel nodes - Standards and controversies.前哨淋巴结术中评估 - 标准与争议。
Breast. 2017 Aug;34 Suppl 1:S64-S69. doi: 10.1016/j.breast.2017.06.031. Epub 2017 Jul 1.
9
Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2- Breast Cancer.绝经后临床 N0 ER+/HER2- 乳腺癌女性中病理性 N2/N3 疾病的流行率。
Ann Surg Oncol. 2022 Nov;29(12):7662-7669. doi: 10.1245/s10434-022-12056-4. Epub 2022 Jun 25.
10
Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?超声评估腋窝是否会增加早期临床淋巴结阴性乳腺癌患者腋窝淋巴结清扫的比例?
BMC Surg. 2022 Mar 3;22(1):80. doi: 10.1186/s12893-022-01530-1.

引用本文的文献

1
Is There a Therapeutic Benefit of Axillary Surgery in Non-Metastatic Breast Cancer? A SEER Cohort Database Study.腋窝手术对非转移性乳腺癌有治疗益处吗?一项监测、流行病学和最终结果(SEER)队列数据库研究。
J Clin Med. 2025 Sep 6;14(17):6314. doi: 10.3390/jcm14176314.
2
Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes.前哨淋巴结1/1阳性和2/2阳性的乳腺癌患者的管理与结局
Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18097-9.

本文引用的文献

1
Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer.前哨淋巴结阳性、腔面型ERBB2阴性乳腺癌患者高淋巴结负荷的预测
JAMA Surg. 2024 Dec 1;159(12):1393-1403. doi: 10.1001/jamasurg.2024.3944.
2
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.完成腋窝淋巴结清扫术以确定 pN2-3 状态作为辅助 CDK4/6 抑制剂治疗的指征:随机、III 期 SENOMAC 试验的事后分析。
Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.
3
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2024 版。
J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.
4
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂:ASCO 指南快速推荐更新。
J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.
5
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.省略腋窝清扫术治疗前哨淋巴结转移乳腺癌。
N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
6
Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?对于激素受体阳性、HER2 阴性乳腺癌且有一个或两个前哨淋巴结阳性的患者,是否应行腋窝清扫术以确定辅助阿贝西利治疗的适应证?
Cancer. 2024 Apr 1;130(7):1052-1060. doi: 10.1002/cncr.35136. Epub 2023 Nov 29.
7
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?是否进行解剖:对于临床淋巴结阴性的绝经后乳腺癌患者,我们能否预测存在 4 个或更多腋窝淋巴结转移?
Ann Surg Oncol. 2023 Dec;30(13):8327-8334. doi: 10.1245/s10434-023-14245-1. Epub 2023 Sep 5.
8
External validation of 87 clinical prediction models supporting clinical decisions for breast cancer patients.87 项支持乳腺癌患者临床决策的临床预测模型的外部验证。
Breast. 2023 Jun;69:382-391. doi: 10.1016/j.breast.2023.04.003. Epub 2023 Apr 17.
9
The majority of 922 prediction models supporting breast cancer decision-making are at high risk of bias.支持乳腺癌决策的922个预测模型中的大多数存在高偏倚风险。
J Clin Epidemiol. 2022 Dec;152:238-247. doi: 10.1016/j.jclinepi.2022.10.016. Epub 2022 Oct 27.
10
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌(monarchE):一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.